Navigation Links
Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
Date:11/9/2010

nsidered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission including the risks under the headings: "Regulatory authorities may not approve our product candidates even if they meet safety and efficacy endpoints in clinical trials.", "We have a history of net losses. We expect to continue to incur substantial and increasing net losses for the foreseeable future, and we may never achieve or maintain profitability.", and "We will need substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations." Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.ALEXZA PHARMACEUTICALS, INC.(a development stage company)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)

(unaudited)Three Months EndedNine Months EndedSeptember 30,September 30,2010200920102009Revenue

$
744$
-$
744$
9,514Operating expenses:Research and development

6,6549,18322,50832,153General and administrative

2,6103,82411,47411,893Restructuring charges

---2,153Acquired in-process research and development

----Total operating expenses

9,26413,00733,98246,199Loss
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014  Iliad Neurosciences, Inc., a company focused ... treating Autism Spectrum Disorders (ASD) announced today that it ... Research Foundation for The State University of New York. ... new biomarker to identify an abnormality in folate transport ... biomarker is expected to be available for research use ...
(Date:9/18/2014)... , September 18, 2014 ... audience, has updated the incredibly successful Serialisation Countdown calendar ... interactive PDF, available at pharmaserialisation.com shows the ... which they will be coming into force. ... longer a matter of "if", but "when" they will ...
(Date:9/18/2014)... , Sept. 18, 2014  Zacks.com announces the ... day the Zacks Equity Research analysts discuss the latest ... Stocks recently featured in the blog include the Avanir Pharmaceuticals ... (Nasdaq: NPSP - Free Report ), Orexigen (Nasdaq: ... MDVN - Free Report ) and Gilead (Nasdaq: ...
Breaking Medicine Technology:Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6
... 14, 2011 Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), a ... (IVD) cancer tests, today announced financial results for its ... for the third quarter ended September 30, 2011 were ... September 30, 2010.  For the nine months ended September ...
... Corporation (NASDAQ: LMNX ) today announced ... at the Defense Threat Reduction Agency,s (DTRA) 2011 ... Conference, which takes place November 14-16, 2011 in ... During the conference, Dr. Altman will present ...
Cached Medicine Technology:Radient Pharmaceuticals Announces FY 2011 Third Quarter Results 2Radient Pharmaceuticals Announces FY 2011 Third Quarter Results 3Luminex Corporation Vice President of Biodefense to Speak at DTRA'S 2011 CBD S&T Conference 2Luminex Corporation Vice President of Biodefense to Speak at DTRA'S 2011 CBD S&T Conference 3
(Date:9/18/2014)... proven it true: exercise is good for you. But ... exercise may have an added benefit for cancer patients ... model of melanoma, found that combining exercise with chemotherapy ... Libonati, an associate professor in the School of Nursing ... Nursing Research, was the senior author on the study, ...
(Date:9/18/2014)... NJ (PRWEB) September 18, 2014 ... firm, announced today that President and co-founder John ... Journal’s Innovation Award Winners for 2014, recognizing the ... him as an emerging executive of the year. ... care and life sciences that continue to shape ...
(Date:9/18/2014)... 2014 Ben Quirk, CEO of Quirk ... Leadership Award by the Savannah Science Seminar in recognition ... throughout the nation and especially in Savannah. , “I ... Ben. “The Savannah Science Seminar is an amazing program ... generations have gone through the program,” he added. Eleventh ...
(Date:9/18/2014)... international scientists have developed a new method to study ... , The Wildlife Conservation Society (WCS)-led research, published today ... describes the use of fecal samples from wild great ... to the virus. This represents a new tool for ... the way Ebola virus is studied and improve our ...
(Date:9/18/2014)... 2014) The National Institutes of Health (NIH) recently ... $1.3 million grant to the Los Angeles Biomedical Research ... development of a vaccine to protect patients from the ... aureus (MRSA). , The National Institute of ... the grant to LA BioMed infectious disease specialists John ...
Breaking Medicine News(10 mins):Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2
... of low health literacy the difference between patients, ... effectively communicate complex medical information is $106 billion ... biopharmaceutical company. To improve the health literacy of professionals ... health literacy study emphasis beginning this fall. The MU ...
... , ... Government Agencies to Increase ROI of IT Infrastructure , ... Reston, VA (PRWEB) February 18, 2010 -- Carahsoft ... Parabonâ Computation , a veteran provider of extreme-scale grid computing software and services. ...
... ... software standardization program at seven hospital laboratories of the Cleveland Clinic in Ohio. ... ... healthcare diagnostic information technology and outreach solutions, has successfully completed system-wide implementation of ...
... Rat studies suggest Victoza could spur rare thyroid tumor, ... THURSDAY, Feb. 18 (HealthDay News) -- The U.S. Food ... January to approve a new diabetes drug, Victoza (liraglutide), ... risk for a rare thyroid cancer. , Victoza, among ...
... (Feb. 17, 2010) Van Andel Research Institute ... sunitinib, a treatment that is currently the first line of ... form of kidney cancer. Most patients who show a ... after one year of treatment. Kidney cancer is among ...
... , ST. PETERS, Mo. , Feb. 18 ... Electronic Materials, Inc., has donated $25,000 to Meds & ... charity dedicated to saving the lives of Haiti ,s malnourished ... Kids produces peanut-based ready-to-use therapeutic food (RUTF) – known in ...
Cached Medicine News:Health News:MU offers training program to improve health literacy 2Health News:Parabon's Frontier Grid Platform Software Now Available on Carahsoft's GSA Schedule 2Health News:Parabon's Frontier Grid Platform Software Now Available on Carahsoft's GSA Schedule 3Health News:Sunquest Completes System-Wide Implementation at Cleveland Clinic Hospital Laboratories 2Health News:FDA Approved Diabetes Drug Despite Hints at Cancer Risk 2Health News:FDA Approved Diabetes Drug Despite Hints at Cancer Risk 3Health News:VARI findings may help patients with deadly kidney cancer 2Health News:MEMC Foundation Donates to Help Fight Malnourishment in Haiti 2Health News:MEMC Foundation Donates to Help Fight Malnourishment in Haiti 3
Electric high speed system....
... High Performance Instrument System was ... for increased power of the ... It provides 60% more torque ... easily handle the most demanding ...
The XK-95 High Speed Drill System sets new technological and performance standards for surgical drill systems....
... Platinum is a compact and quiet, ... at 120 psi/8 bar, it provides ... size with noticeable noise reduction. A ... with an enhanced ergonomic handpiece to ...
Medicine Products: